News
Events
About Pompe Disease
Symptoms
Diagnosis
Pompe Registry
Resources
Patient-Focused Publications
Patients Helping Patients
Research Papers
Publications for Physicians
Testimonials
International Pompe Day
IPA Erasmus Pompe Survey
About the IPA
IPA Board
IPA Members & Contacts
IPA Community Advisory Board
IPA Reviews & Reports
IPA Conferences
IPA Position Papers
Contact
Events
Read our news
About Pompe Disease
Symptoms
Diagnosis
Pompe Registry
Resources
Patient-Focused Publications
Patients Helping Patients
Research Papers
Publications for Physicians
Testimonials
International Pompe Day
IPA Erasmus Pompe Survey
About the IPA
IPA Board
IPA Members & Contacts
IPA Community Advisory Board
IPA Reviews & Reports
IPA Conferences
IPA Position Papers
Contact us
Genzyme Receives Complete Response Letter from FDA on Lumizyme Application
Genzyme Corporation (Nasdaq: GENZ) announced today that it has received a complete response letter from the FDA regarding...
Author:
Genzyme
Archive
March 2, 2009
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe
CRANBURY, N.J., Feb 27, 2009—Amicus Therapeutics announced today that the Company has suspended enrollment for the Phase 2...
Author:
Amicus
Archive
February 26, 2009
European Authorities Approve Larger-Scale Production of Genzyme’s Myozyme
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the European Commission has approved the production of...
Author:
Genzyme
Archive
February 25, 2009
Genzyme Receives Positive Opinion on Myozyme from CHMP in Europe
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the Committee for Medicinal Products for Human Use...
Author:
Genzyme
Archive
February 20, 2009
Myozyme Program Update – Global Version
As Genzyme previously stated in July and again in October 2008, due to greater than expected adoption and...
Author:
Genzyme
Archive
January 14, 2009
Myozyme (2000L) Program Update–US version
As Genzyme previously stated in July 2008 and again in October 2008, due to greater than expected adoption...
Author:
Genzyme
Archive
January 14, 2009
Guidance to the Pompe Community on the Management of Myozyme Supply
This guidance is being distributed to all treating physicians worldwide except those in the European Union (EU). Separate...
Author:
IPA/Genzyme
Archive
January 14, 2009
IPA Statement Regarding the Management of Myozyme Supply – Advice to Patient Groups
Since the first market approval of Myozyme, the IPA has liaised directly with Genzyme LSD Therapeutics to insist...
Author:
IPA
Archive
January 14, 2009
IPA Statement Regarding the Management of Myozyme Supply – Advice to Pompe Patients
Since the first market approval of Myozyme, the IPA has liaised directly with Genzyme LSD Therapeutics to insist...
Author:
IPA
Archive
January 14, 2009
Myozyme Supply FAQs
The IPA has compiled a list of Frequently Asked Questions (FAQs) in order to help answer potentially questions...
Author:
IPA
Archive
January 14, 2009
1
…
30
31
32
33
34
…
38